Market Overview

UPDATE: Protalix Reports Added Data from Phase I/II Trial for PRX-102 for Treatment of Fabry Disease: Improvements of Stabilization in Efficacy Were Demonstrated Across All Disease Parameters

Share:

Get News First. Profit Faster

upsell-button
With Benzinga Professional get unlimited access to ALL content! PLUS:
  • REALTIME NEWSFEED
  • REALTIME AUDIO NEWS
  • FULL CALENDAR SUITE
  • CHAT WITH OUR NEWS DESK

Posted-In: News

 

Related Articles (PLX)